CONNECT WITH US:
linkedin [#161] Created with Sketch.
Explore our easy-to-use
Supplier Directory
Rising Digitalization to Revolutionize Healthcare Systems Boosting Pharmacy Automation Market
Artificial Intelligence in Pharmacies Would Lead to Future Trends in Global Pharmacy Automation Market.
Nov 06, 2023
robotics and pharmacy automation

NEWARK, DE - It is anticipated that the global pharmacy automation market would grow from US$ 6.1 billion in 2023 to US$ 13.3 billion by 2033. From 2023 to 2033, the market is anticipated to grow at a compound annual growth rate of 8.1%.

Robotic systems automate several physical tasks involved in pharmacy operations, such as dispensing medications, packaging prescriptions, and transporting medications throughout the pharmacy. This enables pharmacists to focus on more clinical tasks, such as patient counseling and medication management.

Artificial intelligence (AI) and machine learning (ML) are increasingly used in pharmacy automation systems for a wide range of tasks in the pharmacy, including prescription filling, inventory management, and patient counseling. For example, AI-powered prescription filling systems can automatically fill prescriptions accurately and quickly, reducing the risk of human error.

Cloud-based systems are more affordable and easier to implement than traditional on-premises systems. They also offer greater flexibility and scalability, making them a good option for pharmacies of all sizes, stimulating the adoption of cloud-based pharmacy automation systems.

"Interoperability allows pharmacy automation systems to communicate with other systems, such as electronic health records (EHRs) and laboratory information systems (LISs). This can improve the efficiency of pharmacy operations and reduce the risk of errors, increasing focus on interoperability between pharmacy automation systems and other healthcare IT systems," opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Key Takeaways:

  • The global pharmacy automation market is estimated to register a CAGR of 8.1%, reaching a valuation of US$ 13.3 billion by 2033.
  • The market grew at a CAGR of 10.2% during the historical period from 2018 to 2022.
  • The United States is anticipated to dominate the global market by registering an 8.3% CAGR during the forecast period.
  • The market in China is anticipated to progress at a CAGR of 8.7% through 2033.
  • The market in Japan is expected to secure a CAGR of 9.3% during the forecast period.

Key Players and Strategies for Success in the Pharmacy Automation Market

In recent years, there has been a surge in investments and collaborations within the industry with venture capital firms and businesses. These strategic partnerships and financial investments aim to accelerate research and development, scale production, and expand market reach.

Recent Developments in the Pharmacy Automation Market:

  • In 2023, Omnicell launched its new specialty pharmacy services offering to help health systems establish and optimize specialty pharmacy programs. This service includes a suite of pharmacy automation solutions, such as robotic dispensing systems and cloud-based inventory management software.
  • In 2021, BD launched its new AutoLink IV compounding system. This system automates the compounding of intravenous (IV) medications, reducing the risk of errors and improving the efficiency of pharmacy operations.
  • In 2022, Parata Systems launched its new RxFill 360 dispensing system. This system uses AI and robotics to automate prescription filling, from order entry to labeling.

Key Players:

  • Becton
  • Cerner Corporation
  • Parata Systems LLC
  • Yuyama Co. Ltd
  • PerceptiMed Inc
  • McKesson Corporation
  • Capsa Solutions LLC
  • Omnicell Inc
  • Dickinson and Company
  • Arxium Inc
  • Scriptpro LLC
  • Swisslog Holdings AG
  • Rxsafe LLC

Pharmacy Automation Market Segmentation:

By Product:

  • Medication Dispensing Systems
  • Automated Medication Compounding Systems
  • Packaging and Labeling Systems
  • Storage and Retrieval Systems
  • Tabletop Tablet Counters

By End-use Sector:

  • Inpatient Pharmacies
    • Acute Care Settings
    • Long Term Care Facilities
  • Outpatient Pharmacies
    • Outpatient/Fast Track Clinics
    • Hospital Retail Settings
  • Pharmacy Benefit Management Organization and Mail Order Pharmacies
  • Retail Pharmacies

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan (APEJ)
  • Japan
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Latest Industry news
View all Industry News
Bayer Logo
AskBio Earns FDA Rare Pediatric & Orphan Drug Status for AB-1003 in Limb-Girdle Muscular Dystrophy
Nov 07, 2024

Research Triangle Park, N.C.  – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

hotomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia (AML), a cancer of white blood cells.
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia
Nov 01, 2024

The Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).

White oxy pills
Protega Pharmaceuticals Gains FDA Approval for Abuse-Deterrent ROXYBOND™ 10 mg Pain Tablet
Oct 29, 2024

PRINCETON, N.J - Protega Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved ROXYBOND™ (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ROXYBOND is the first and only FDA-approved abuse-deterrent IR 10 mg oxycodone formulation that is expected to reduce abuse by intranasal and intravenous routes.